{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension&page=21",
    "query": {
      "intervention": "Open Label Extension",
      "page": 21
    },
    "page_size": 10
  },
  "pagination": {
    "page": 21,
    "page_size": 10,
    "total_count": 2286,
    "total_pages": 229,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension&page=22&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Open+Label+Extension&page=20&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-26T21:34:24.377Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06512883",
      "title": "A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eosinophilic Granulomatosis With Polyangiitis (EGPA)",
        "Hypereosinophilia Syndrome (HES)"
      ],
      "interventions": [
        {
          "name": "Benralizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 14,
      "start_date": "2025-04-17",
      "completion_date": "2029-05-14",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-10-26T21:34:24.377Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Cincinnati, Ohio • Highland Hills, Ohio",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Highland Hills",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06512883"
    },
    {
      "nct_id": "NCT00663429",
      "title": "Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "Atiprimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Callisto Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2007-11",
      "completion_date": "2010-03",
      "has_results": false,
      "last_update_posted_date": "2011-08-31",
      "last_synced_at": "2026-10-26T21:34:24.377Z",
      "location_count": 2,
      "location_summary": "Little Rock, Arkansas • New York, New York",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00663429"
    },
    {
      "nct_id": "NCT03335488",
      "title": "Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Urea Cycle Disorder"
      ],
      "interventions": [
        {
          "name": "RAVICTI",
          "type": "DRUG"
        },
        {
          "name": "NaPBA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "Up to 99 Years"
      },
      "enrollment_count": 16,
      "start_date": "2018-02-20",
      "completion_date": "2022-12-20",
      "has_results": true,
      "last_update_posted_date": "2024-07-01",
      "last_synced_at": "2026-10-26T21:34:24.377Z",
      "location_count": 6,
      "location_summary": "Gainesville, Florida • New York, New York • Cleveland, Ohio + 3 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03335488"
    },
    {
      "nct_id": "NCT03870880",
      "title": "Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Risperidone ISM 75 mg",
          "type": "DRUG"
        },
        {
          "name": "Risperidone ISM 100 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rovi Pharmaceuticals Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 215,
      "start_date": "2017-08-25",
      "completion_date": "2020-01-08",
      "has_results": true,
      "last_update_posted_date": "2022-03-25",
      "last_synced_at": "2026-10-26T21:34:24.377Z",
      "location_count": 13,
      "location_summary": "Rogers, Arkansas • Garden Grove, California • Long Beach, California + 10 more",
      "locations": [
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Pico Rivera",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03870880"
    },
    {
      "nct_id": "NCT05217927",
      "title": "Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Rimegepant 75mg daily dosing",
          "type": "DRUG"
        },
        {
          "name": "Rimegepant 75mg every other day dosing",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator dosing",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1415,
      "start_date": "2022-03-04",
      "completion_date": "2024-12-11",
      "has_results": true,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-10-26T21:34:24.377Z",
      "location_count": 30,
      "location_summary": "Tempe, Arizona • Colton, California • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05217927"
    },
    {
      "nct_id": "NCT05869669",
      "title": "RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dementia With Lewy Bodies"
      ],
      "interventions": [
        {
          "name": "Neflamapimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EIP Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2023-05-01",
      "completion_date": "2025-06-16",
      "has_results": true,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-10-26T21:34:24.377Z",
      "location_count": 29,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05869669"
    },
    {
      "nct_id": "NCT02531113",
      "title": "Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "RPC1063",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 69,
      "start_date": "2015-10-09",
      "completion_date": "2019-11-28",
      "has_results": true,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-10-26T21:34:24.377Z",
      "location_count": 13,
      "location_summary": "Tucson, Arizona • Largo, Florida • Palmetto Bay, Florida + 10 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Palmetto Bay",
          "state": "Florida"
        },
        {
          "city": "Suwanee",
          "state": "Georgia"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02531113"
    },
    {
      "nct_id": "NCT04049097",
      "title": "Arimoclomol in Sporadic Inclusion Body Myositis - Open Label Extension Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Inclusion Body Myositis"
      ],
      "interventions": [
        {
          "name": "Arimoclomol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ZevraDenmark",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 121,
      "start_date": "2019-05-20",
      "completion_date": "2021-11-15",
      "has_results": true,
      "last_update_posted_date": "2023-09-15",
      "last_synced_at": "2026-10-26T21:34:24.377Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Irvine, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04049097"
    },
    {
      "nct_id": "NCT03337542",
      "title": "AR101 Real-World Open-Label Extension Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "AR101",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Aimmune Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "4 Years to 17 Years"
      },
      "enrollment_count": 243,
      "start_date": "2017-10-18",
      "completion_date": "2019-09-20",
      "has_results": true,
      "last_update_posted_date": "2021-11-02",
      "last_synced_at": "2026-10-26T21:34:24.377Z",
      "location_count": 55,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03337542"
    },
    {
      "nct_id": "NCT00288509",
      "title": "Open-label Extension Study of AbobotulinumtoxinA (Dysport®) for the Treatment of Cervical Dystonia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cervical Dystonia"
      ],
      "interventions": [
        {
          "name": "Botulinum toxin type A",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 108,
      "start_date": "2006-02",
      "completion_date": "2008-01",
      "has_results": true,
      "last_update_posted_date": "2022-09-28",
      "last_synced_at": "2026-10-26T21:34:24.377Z",
      "location_count": 14,
      "location_summary": "Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00288509"
    }
  ]
}